When macrophages from patients with cryopyrin-associated autoinflammatory syndrome are treated with β-(1,3)-glucan, they have reduced caspase-1 activation and IL-1β release compared with untreated macrophages [71], which could be therapeutically beneficial for these patients. This evidence concerns the gene CASP1 and autoinflammatory syndrome.